Abstract 947P
Background
Immunotherapy, targeted therapy and their combination has been developed as first-line treatment for advanced HCC.The combination therapy has improved the antitumor effects compared with targeted therapy,but tended to have higher incidence of adverse reactions.This study aims to assess the efficacy and safety of Cadonilimab, a humanized, tetravalent, bispecific antibody targeting PD-1 and CTLA-4,with lenvatinib(len) in first-line treatment of HCC.
Methods
This multicenter, open-label, phase Ib/II study included patients with histologically or clinically confirmed unresectable HCC to receive either 6mg/kg Cadonilimab every 2 weeks plus len(cohort A) or 15mg/kg Cadonilimab every 3 weeks plus len(cohort B). The primary endpoint was objective response rate (ORR) by RECIST v1.1, the secondary endpoint includes safety, progression-free disease (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR) and time to response (TTR).
Results
A total of 59 patients were enrolled (cohort A, n=31; cohort B, n=28).As the date of data cutoff July 28,2023, the median follow-up duration was 27.4 months.ORR was 35.5% (95% CI, 23.6-49.1) in cohort A and 35.7% (95% CI, 18.6-55.9) in cohort B. The median PFS was 8.6 months (95%CI, 5.2-17.9) and 9.8 months (6.9-15.2), respectively.The median OS was 27.1 months (95%CI,15.7,NE) for cohort A,while it was not reached for cohort B. Grade ≥ 3 TRAEs occured in 66.1% of patients, and serious AEs were reported in 39.0% of cases.All AEs were expected and manageable.All the deaths were related to disease progression and not related to Cadonilimab. Table: 947P
Summary of Efficacy analysis and tumor response by investigator review per RECIST v1.1
Cohort A n=31 | Cohort B n=28 | |
Objective response rate,n(%) | 11 (35.5) | 10 (35.7) |
Disease control rate,n(%) | 28 (90.3) | 26 (92.9) |
mTTP,m | 2.8 | 1.4 |
Min-Max | 1.3-8.3 | 1.3-6.9 |
mDOR,m | 13.6 | 13.7 |
95% CI | 4.14, NE | 3.52, NE |
mPFS,m | 8.61 | 9.82 |
95% CI | 5.19,15.15 | 6.87,15.18 |
mOS,m | 27.1 | NR |
95% CI | 15.7,NE | 19.3,NE |
Conclusions
This novel combination therapy of PD-1/CTLA4 bispecific monoclonal antibody and lenvatinib showed promising efficacy and manageable toxicity that could provide an option of treatment in first-line setting of aHCC.
Clinical trial identification
NCT04444167.
Editorial acknowledgement
Legal entity responsible for the study
Akeso Biopharma, Inc.
Funding
Akeso Biopharma, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18